Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN0025 with Chemoradiation in Stage III NSCLC
NCT05358691Phase 1Withdrawn
- Sponsor
- Rutgers University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of palupiprant in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Rutgers University. Primary endpoints: Eastern Cooperative Oncology Group Performance Status at 2 years, Safety and Toxicity and 5 more. Planned start Nov 2024; status: withdrawn.
02
Drugs
palupiprant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05358691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358691.